Weidu Capital
Beijing, China
Overview
WeDo Capital Management is a Beijing-based venture capital and investment firm focused on healthcare and technology. It began operation on February 2, 2016, with its headquarters in Beijing in China
- Total investments
- 2
- Lead investments
- 0
- Investments · 12mo
- 1
- Active investors
- 0
Sector focus
- Finance
- Financial Services
- Impact Investing
- Venture Capital
Investment portfolio
- HemaCell
Participated · Series B · Jun 2026
HemaCell develops cell therapeutics centered on the platelet lineage, with a flagship product described as the world's first megakaryocyte injection and a pipeline of platelet injection candidates. The company aims to address blood supply shortages and reduce adverse consequences associated with blood transfusions, while pursuing platelet-derived therapeutics for aging-related indications. HemaCell is advancing multiple clinical trials for its lead program and plans to use recent Series B proceeds to support those trials and pipeline development. Management has signaled plans for a pre-IPO fundraising within the year to build manufacturing bases and expand production capacity. Founder Zhu Fangfang stated the company will continue steady, market- and clinic-driven development and rapidly pursue capital market milestones to enable eventual product launches.
Team
No current team members are available.